8 recruiting, 7 completed, 4 active not recruiting, 4 not yet recruiting. 20 Phase 1, 6 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 6, Recruiting 6, Active not recruiting 4, Not yet recruiting 3, Terminated 1 |
| Phase 2 | 6 | Recruiting 4, Not yet recruiting 2 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Advanced Solid Tumors Cancer: new trials by email Literature Review of Advanced Solid Tumors Cancer trials Research Report on Advanced Solid Tumors Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion. GT201, IL-2 and PD-1 - Advanced Solid Tumors Cancer | Phase 1 / Phase 2 | Not yet recruiting | Gritbio Medicine, Inc. | 63 | 2026-11-01 | 2026-08-14 |
| Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer ODM-216 - Advanced Solid Tumors Cancer | Phase 1 / Phase 2 | Recruiting | Orion Corporation, Orion Pharma | 195 | 2026-09-03 | 2026-09-24 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| First-In-Human Study of KHN922 for Injection KHN922 for injection - Advanced Solid Tumors Cancer | Phase 1 / Phase 2 | Not yet recruiting | Chengdu Kanghong Biotech Co., Ltd. | 276 | 2026-04-01 | 2026-04-09 |
| A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation GFH375 - Advanced Solid Tumors Cancer, PDAC | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 126 | 2025-10-21 | 2025-12-02 |
| PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer PQ203 - Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer | Phase 1 | Recruiting | ProteinQure Inc. | 80 | 2025-09-16 | 2026-02-23 |
| A Study of KC1086 in Patients With Advanced Solid Tumors KC1086 - Advanced Solid Tumors Cancer | Phase 1 | Not yet recruiting | Beijing Konruns Pharmaceutical Co., Ltd. | 66 | 2025-08-01 | 2025-08-12 |
| Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) Biopsy - Cancer, Immunotherapy | Recruiting | Elephas | 2000 | 2025-04-14 | 2026-06-29 | |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. NDI-219216 - Advanced Solid Tumors Cancer, MSI-H Cancer | Phase 1 / Phase 2 | Recruiting | Nimbus Wadjet, Inc. | 134 | 2025-03-31 | 2026-05-06 |
| ORB-021 In Patients With Advanced Solid Tumors ORB-021 - Advanced Solid Tumors Cancer | Phase 1 | Recruiting | Orionis Biosciences Inc | 36 | 2024-11-21 | 2026-08-26 |
| Clinical PhenoAge and Mortality After Unplanned Hospital Admission in Metastatic Cancer Retrospective Assessment of Clinical PhenoAge and Prognostic Scores - Advanced Solid Tumors Cancer, Hospitalizations | Completed | Ankara Etlik City Hospital | 4321 | 2022-11-05 | 2026-11-12 | |
| ET-SPACE Whole-Body Infrared Hyperthermia in Patients With Advanced Solid Tumors Advanced Solid Tumors, Advanced Solid Tumors Cancer | Recruiting | Zhejiang Hospital | 500 | 2022-01-01 | 2026-08-28 | |
| Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors ABBV-637, Docetaxel, Osimertinib - Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Active not recruiting | AbbVie | 81 | 2021-02-23 | 2025-07-03 |
| First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI - Advanced Solid Tumors Cancer | Phase 1 | Completed | AbbVie | 101 | 2020-06-03 | 2025-09-25 |
| A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma ABBV-368, Tilsotolimod, Nab-paclitaxel - Advanced Solid Tumors Cancer | Phase 1 | Completed | AbbVie | 30 | 2020-01-22 | 2023-02-27 |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors Livmoniplimab, Budigalimab - Advanced Solid Tumors Cancer | Phase 1 | Active not recruiting | AbbVie | 364 | 2019-02-21 | 2025-05-25 |
| A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors ABBV-399 - Advanced Solid Tumors Cancer | Phase 1 | Completed | AbbVie | 9 | 2017-11-06 | 2019-03-14 |
| A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) ABBV-321 - Advanced Solid Tumors Cancer | Phase 1 | Completed | AbbVie | 62 | 2017-10-10 | 2021-05-06 |
| A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) ABBV-176 - Advanced Solid Tumors Cancer | Phase 1 | Terminated | AbbVie | 19 | 2017-07-03 | 2018-11-29 |
Showing 20 of 24. Sign in to see all of them.
Neoplasms (14) · Carcinoma, Non-Small-Cell Lung (7) · Colorectal Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Melanoma (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Adrenocortical Carcinoma (1) · Breast Neoplasms (1) · Cancer Pain (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Squamous Cell (1)
Neoplasms by Site (13) · Neoplasms by Histologic Type (9) · Carcinoma (8) · Neoplasms, Glandular and Epithelial (8) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Diseases (7) · Lung Neoplasms (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Thoracic Neoplasms (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6)
budigalimab (4) · Cetuximab (2) · Gemcitabine (2) · Nivolumab (2) · Taxes (2) · osimertinib (2) · telisotuzumab vedotin (2) · 130-nm albumin-bound paclitaxel (1) · ABBV-428 (1) · Biopsy (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Fluorouracil (1) · Immune Checkpoint Inhibitors (1) · Injections (1)
AbbVie (11) · Genfleet Therapeutics (Shanghai) Inc. (2) · Ankara Etlik City Hospital (1) · Beijing Konruns Pharmaceutical Co., Ltd. (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Elephas (1) · Gritbio Medicine, Inc. (1) · Natera, Inc. (1) · Nimbus Wadjet, Inc. (1) · Orion Corporation, Orion Pharma (1) · Orionis Biosciences Inc (1) · ProteinQure Inc. (1) · Zhejiang Hospital (1)
United States (14) · France (9) · Spain (9) · Australia (8) · Japan (7) · Taiwan (6) · Israel (5) · South Korea (5) · Canada (4) · China (4) · Belgium (2) · Germany (2) · Italy (2) · Netherlands (2) · Puerto Rico (2)
Anita Scheuber, MD, PhD (1) · Glenn Hanna, MD (1) · Lin Shen, MD (1) · Qing Zhou (1) · Robert Petit, PhD (1) · Xin Wang (1) · Yan Zhang (1)
PMID 30285518, PMID 32524319, PMID 33608377, PMID 33675179, PMID 34426443, PMID 36288547, PMID 36814898, PMID 39534099, PMID 39805351, PMID 41956545
2016 (4), 2014 (1), 2019 (1), 2023 (1)